CNCRのチャート
CNCRの企業情報
| symbol | CNCR |
|---|---|
| 会社名 | |
| 分野（sector） | ― |
| 産業（industry） | ― |
| 業種 | ― |
| 概要 | 事業概要 -- |
| 本社所在地 | -- |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | -- |
| 市場名 | -- |
| ipoyear | ―年 |
| 従業員数 | - |
| url | ― |
| nasdaq_url | https://www.nasdaq.com/symbol/cncr |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 23.16 |
| 時価総額（marketcap） | 52110000 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
CNCRのテクニカル分析
CNCRのニュース
Top Momentum ETF Plays: MNA, GREK, XPH, CNCR, EWJ, BJK, HEFA 2020/09/16 13:53:33 The Street
Top 25 momentum candidates that are displaying positive price movement, improving relative strength and strong technical signals.
3 ETFs For More Moderna Bets 2020/05/19 13:29:37 Benzinga
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA ) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress. Those headlines prompted some analysts to say Moderna could be the first to market with a credible vaccine for the sometimes-fatal respiratory illness, and with those comments came at least a trio of bullish price target revisions into triple-digit territory. For all the ebullience surrounding Moderna this year — and there's been plenty as highlighted by a 2020 climb of 309% — the stock isn't often mentioned in relation to exchange traded funds. A few ETFs have robust Moderna holdings. The stock closed at $80 Monday, and with some price targets residing in the $100 to $105 area, there could be more upside ahead, meaning the following ETFs could be worth considering. Loncar Cancer Immunotherapy ETF (CNCR) Sixty-two ETFs have some exposure … Full story available on Benzinga.com
Top Momentum ETF Plays: MNA, GREK, XPH, CNCR, EWJ, BJK, HEFA 2020/09/16 13:53:33 The Street
Top 25 momentum candidates that are displaying positive price movement, improving relative strength and strong technical signals.
3 ETFs For More Moderna Bets 2020/05/19 13:29:37 Benzinga
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA ) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress. Those headlines prompted some analysts to say Moderna could be the first to market with a credible vaccine for the sometimes-fatal respiratory illness, and with those comments came at least a trio of bullish price target revisions into triple-digit territory. For all the ebullience surrounding Moderna this year — and there's been plenty as highlighted by a 2020 climb of 309% — the stock isn't often mentioned in relation to exchange traded funds. A few ETFs have robust Moderna holdings. The stock closed at $80 Monday, and with some price targets residing in the $100 to $105 area, there could be more upside ahead, meaning the following ETFs could be worth considering. Loncar Cancer Immunotherapy ETF (CNCR) Sixty-two ETFs have some exposure … Full story available on Benzinga.com